Glucagon-like peptide-1 profile during oral glucose tolerance test in young people

Płaczkowska, Sylwia; Kokot, Izabela; Pawlik-Sobecka, Lilla; Piwowar, Agnieszka

doi:10.5603/dk.2017.0026

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It increases the insulin sensitivity of muscle cells, reduces cell proliferation in inflammation, and increases surfactant production. GLP-1 also increases diuresis, positively influences bone formation processes, reduces degenerative processes in liver cells, has a beneficial effect on the functioning of heart cells, and plays a cardioprotective role by improving the function of the left ventricle [53]. After the approval of exenatide for the treatment of type 2 diabetes, several pharmaceutical companies initiated diverse efforts to stimulate the GLP-1 receptor more effectively and with a longer duration of action [54].…”

Section: Description Of the State Knowledgementioning

confidence: 99%

GLP-1 analogs: a comparison of new anti diabetic medications - presenting benefits and risks

Dębik,

Szydłowski,

Żurowska

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose: Diabetes has emerged as a global lifestyle disease, with an alarming rise in cases, particularly of type 2 diabetes. In Poland, over 3 million people are diagnosed, and an estimated 4 million cases are expected by 2030. Effective treatment involves a multifaceted approach, including dietary intervention, physical activity, and pharmacological options. Incretins, such as glucagon-like peptide-1 (GLP-1), play a pivotal role in carbohydrate metabolism regulation, and GLP-1 analogs have become essential in managing type 2 diabetes. This paper explores the development and mechanisms of GLP-1 analogs, detailing their impact on insulin secretion, gastric emptying, and weight reduction. Description of the state knowledge: Various GLP-1 receptor agonists, including exenatide, liraglutide, dulaglutide, semaglutide, and the novel tirzepatide, are discussed. These drugs exhibit diverse pharmacokinetics, modes of administration, and effects on glucose metabolism and weight. Despite their efficacy, there is a concerning trend of off-label use, particularly for obesity treatment, leading to shortages for patients with valid prescriptions. This misuse is fueled by para-advertising on social media platforms, contributing to a surge in prescriptions and reimbursement costs. To address this, guidelines for GLP-1 analog use in obesity treatment are proposed, emphasizing the need for a stable drug supply and normalizing drug availability. Summary: In 2023, concerns intensified with reports of counterfeit GLP-1 analogs, prompting regulatory interventions. The paper concludes by underscoring the critical role GLP-1 analogs play in diabetes and obesity treatment, while emphasizing the importance of responsible prescription practices, guidelines adherence, and regulatory vigilance to ensure patient safety and mitigate the risks associated with misuse and counterfeit drugs.

show abstract

Section: Description Of the State Knowledgementioning

confidence: 99%